



I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231

on JULY 8th, 2002

Date of Deposit

John Murray

Name of applicant, assignee or
Registered Representative

John Murray
Signature

JULY 8th, 2002

Date of Signature

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

#8

Our Case No. 8642/94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Nabel *et al.*

Serial No.: 09/708,276

Filing Date: Nov 7th, 2000

For: Method for Treating Vascular
Proliferative Diseases with p27 and
Fusions Thereof

Examiner: Sandals, William O

Group Art Unit No.: 1636

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits but before the mailing date of a final Office Action. The fee required under 37 C.F.R. § 1.97(p) is included. However, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the following cited documents are enclosed:

B1	U.S. 6,355,774	Mar 12, 2002	Massague et al.
B2	U.S. 6,316,208	Nov 13, 2001	Roberts et al.
B3	U.S. 6,242,575	Jun 5, 2001	Massague et al.
B4	U.S. 5,688,665	Nov 18, 1997	Massague et al.
B5	Craig et al. Proc. Annu. Meet. Assoc. Cancer Res. 37: A13 "Effects of a Recombinant Adenovirus Vector Expressing p27 on Cell Growth, Cell Cycle, Cyclin Kinases and Apoptosis"		

If, for any reason, the Examiner feels that an interview would be helpful to resolve any issues, he is respectfully requested to contact the undersigned attorney at (312) 321-4229.

Respectfully submitted,

Date: July 8th, 2002

John Murray
John Murray, Ph.D.
Registration No. 44,251
Attorney for Applicant

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200